SCHEMBL319646

SCHEMBL319646

SCCNC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.63
KCNN4 O15554 3/20 0.56
DUT P33316 3/20 0.41
HDAC3 O15379 5/20 0.36
HDAC4 P56524 5/20 0.36
HDAC1 Q13547 5/20 0.36
HDAC7 Q8WUI4 5/20 0.36
HDAC2 Q92769 5/20 0.36
HDAC10 Q969S8 5/20 0.36
HDAC11 Q96DB2 5/20 0.36
HDAC8 Q9BY41 5/20 0.36
HDAC6 Q9UBN7 5/20 0.36
HDAC9 Q9UKV0 5/20 0.36
HDAC5 Q9UQL6 5/20 0.36
TSHR P16473 2/20 0.33
IDO1 P14902 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TAAR1 Q96RJ0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12264131 0.85 KIF11 (0.74) KIF11KCNN4DUTTSHRALDH1A1
SCHEMBL574703 0.84 KIF11 (0.47) KIF11KCNN4IDO1
SCHEMBL4254994 0.82 KCNN4 (0.44) KIF11KCNN4DUTTSHRIDO1
SCHEMBL12264133 0.81 KIF11 (0.68) KIF11KCNN4DUTTSHRALDH1A1
SCHEMBL29679194 0.79 KIF11 (0.65) KIF11KCNN4DUTTSHRALDH1A1
SCHEMBL147990 0.79 KIF11 (0.65) KIF11KCNN4DUTALDH1A1
SCHEMBL9781955 0.77 KIF11 (0.63) KIF11KCNN4DUTTSHRALDH1A1
SCHEMBL1809571 0.77 KIF11 (0.63) KIF11KCNN4DUTTSHRALDH1A1
SCHEMBL8961063 0.77 KCNN4 (0.68) KIF11KCNN4DUTTAAR1
SCHEMBL1105545 0.77 KIF11 (1.00) KIF11KCNN4DUTTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3066106-A1 STABLE PANTETHEINE DERIVATIVES FOR THE TREATMENT OF PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (PKAN) AND METHODS FOR THE SYNTHESIS OF SUCH COMPOUNDS Acies Bio d.o.o. (SI) 2016-09-14 EP claimed
WO-2015063177-A1 STABLE PANTETHEINE DERIVATIVES FOR THE TREATMENT OF PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (PKAN) AND METHODS FOR THE SYNTHESIS OF SUCH COMPOUNDS ACIES BIO D.O.O. (SI) 2015-05-07 WO claimed
CN-120059164-A PH responsive polypeptide mimic and preparation method and application thereof 华东理工大学 2025-05-30 CN disclosed
CN-113185740-B Method for improving antibacterial activity and biocompatibility of substrate surface 华东理工大学 2023-09-22 CN disclosed
CN-116554461-A Use of polymers to promote endothelialization of interventional/implant materials 华东理工大学 2023-08-08 CN disclosed
US-20220133753-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES CHARACTERIZED BY INSUFFICIENT PANTOTHENATE KINASE ACTIVITY VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) 2022-05-05 US disclosed
EP-2459227-B1 Prodrugs containing an aromatic amine connected by an amide bond to a carrier ASCENDIS PHARMA AS (DK) 2021-03-17 EP disclosed
EP-2741782-B1 PROTEIN CARRIER-LINKED PRODRUGS ASCENDIS PHARMA AS (DK) 2020-05-06 EP disclosed
CN-110478495-A Target conjugate and its particle and preparation TARVEDA THERAPEUTICS INC 2019-11-22 CN disclosed
CN-106573077-B Targeted conjugates and particles and formulations thereof 塔弗达治疗有限公司 2019-07-30 CN disclosed
US-20170227545-A1 REACTIVITY-BASED SCREENING FOR NATURAL PRODUCT DISCOVERY THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2017-08-10 US disclosed
US-5079358-A Humans; leukemia KYOWA HAKKO KOGYO CO., LTD. (JP) 1992-01-07 US disclosed
EP-0347749-A2 Pyrazoloacridone derivatives with anti-tumoral activity KYOWA HAKKO KOGYO CO., LTD. (JP) 1989-12-27 EP disclosed
US-4863935-A Mitomycin compounds having useful anti-tumor activity KYOWA HAKKO KOGYO K.K. (JP) 1989-09-05 US disclosed
EP-0272063-A1 Mitomycin derivatives KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) 1988-06-22 EP disclosed
EP-0002564-B1 DERIVATIVES OF 7-OXO-1-AZABICYCLO(3.2.0)-HEPT-2-ENE-2-CARBOXYLIC ACID, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES BEECHAM GROUP PLC (GB) 1984-06-20 EP disclosed
US-4347181-A Intermediates for producing bicyclic β-lactam-antibiotics BEECHAM GROUP LIMITED (GB) 1982-08-31 US disclosed
US-4289696-A BETA-LACTAMASE INHIBITORY AGENTS WHICH ENHANCE ACTIVITY OF A PENICICILLIN OR CEPHALOSPORIN BEECHAM GROUP LIMITED (GB) 1981-09-15 US disclosed
US-4223038-A THIENAMYCINS BEECHAM GROUP LIMITED (GB) 1980-09-16 US disclosed
EP-0002564-A1 Derivatives of 7-oxo-1-azabicyclo(3.2.0)-hept-2-ene-2-carboxylic acid, their preparation, pharmaceutical compositions containing them and intermediates BEECHAM GROUP PLC (GB) 1979-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220133753-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES CHARACTERIZED BY INSUFFICIENT PANTOTHENATE KINASE ACTIVITY PANK1, PANK3, PHKG1 KIF11 4141/4885KCNN4 3189/4885DUT 602/4885
US-20170227545-A1 REACTIVITY-BASED SCREENING FOR NATURAL PRODUCT DISCOVERY NQO1, NCL, NANS KIF11 3852/4885KCNN4 3864/4885DUT 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.